This HTML5 document contains 156 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n9http://dx.doi.org/10.1093/ANNONC/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q39961162
rdf:type
wikibase:Item
schema:description
artikulong pang-agham articol științific 2009年学术文章 bilimsel makale mokslinis straipsnis vitskapeleg artikkel научна статия գիտական հոդված мақолаи илмӣ tieteellinen artikkeli article scientific სამეცნიერო სტატია artigo científico (publicado na 2009) 2009年學術文章 artículo científico publicado en 2009 2009年学术文章 wissenschaftlicher Artikel wetenschappelijk artikel artículu científicu espublizáu en 2009 научни чланак artykuł naukowy artikull shkencor 2009年学术文章 article científic bài báo khoa học наукова стаття, опублікована в липні 2009 articolo scientifico 2009년 논문 artigo científico vetenskaplig artikel naučni članak επιστημονικό άρθρο מאמר מדעי vedecký článok 2009年学术文章 سائنسی مضمون scientific article 2009年學術文章 2009 nî lūn-bûn 2009年學術文章 2009年学术文章 vědecký článek мақолаи илмӣ مقالهٔ علمی ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научная статья مقالة علمية vitenskapelig artikkel บทความทางวิทยาศาสตร์ scienca artikolo 2009年學術文章 2009年の論文 teaduslik artikkel article scientifique (publié 2009) 2009年學術文章 tudományos cikk artigo científico (publicado na 2009) videnskabelig artikel (udgivet 2009) 2009年學術文章 научни чланак
p:P577
wds:Q39961162-4CDBA733-15E6-4AFE-8531-4D8B0193AE94
wdt:P577
2009-07-22T00:00:00Z
p:P2860
wds:Q39961162-CE0738B0-BF20-4283-BB45-939B6EE129CC wds:Q39961162-AAA19849-7F7E-4912-B0D6-D4B22667D628 wds:Q39961162-B05FFA45-5F8D-43C9-B8A2-F58003976BA5 wds:Q39961162-668136B4-FD78-4FD4-B3D5-CCBD439B800F wds:Q39961162-8E901EE4-7329-48B2-9C5B-4B89131370CB wds:Q39961162-FFB5F455-F42B-4D78-8AD2-1BD396C11AB6 wds:Q39961162-E51A7841-6AC8-4BB1-B717-B4FDD7D8B1D9 wds:Q39961162-EBD905B2-CCEF-4AF4-8274-715569C3655F wds:Q39961162-DB0418BD-6B4E-4DFC-9650-18990DF1933F wds:Q39961162-DFFA1C52-9996-42CB-8E12-0085580E3798 wds:Q39961162-E3EBCB29-3424-4B8A-9F95-BDA8F33A826C wds:Q39961162-59DD35AE-8983-41FD-85B7-E9E6494AC747 wds:Q39961162-3578CF5D-05C8-4731-8B27-B5E13A619AD6 wds:Q39961162-48708E11-C51A-47FA-89D8-B94B4E797298 wds:Q39961162-31FB4AB9-F26F-4D50-9C45-685211B87A0B wds:Q39961162-3418CFD9-807B-4B95-A020-CCD281E740BE
wdt:P2860
wd:Q46423648 wd:Q28255226 wd:Q33343374 wd:Q53396920 wd:Q35087225 wd:Q33366094 wd:Q73492635 wd:Q44978589 wd:Q34285880 wd:Q33358900 wd:Q34524041 wd:Q33367321 wd:Q31003726 wd:Q45126369 wd:Q74176647 wd:Q27824766
p:P2093
wds:Q39961162-F0826F5F-4B24-4D35-AD32-A4CA7D7AF415 wds:Q39961162-DA779CC1-1380-4B9C-AE95-4E7FCD7B3BD3 wds:Q39961162-B46540F4-A614-4661-909A-79999E099084 wds:Q39961162-C4764DF0-F56C-4EDC-A4E0-811E543DD3D3 wds:Q39961162-8A8D2064-2BE6-41DD-AEFE-8E501A622E13 wds:Q39961162-9B281443-E4C3-492F-820E-B37DC133E876 wds:Q39961162-A8E6D245-3670-4C06-95C7-46AEE842CCD5 wds:Q39961162-94D643B9-D6F6-4503-A88C-16EE3D4D9F5C wds:Q39961162-9AA640A1-63B2-4C1C-9E23-3C9A60B03F43 wds:Q39961162-26270B78-C04D-40AC-94C7-F9926F584B49 wds:Q39961162-286ECD36-0C1B-4026-9D72-3C0F546842A4
wdt:P2093
D W Northfelt D W Hillman F Palmieri S S Gamini M Salim E A Perez D M Anderson R Niedringhaus W W Tan A M Bernath P J Stella
rdfs:label
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
skos:prefLabel
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
schema:name
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group
p:P1476
wds:Q39961162-26A25D25-8FFD-46B9-9288-04939E672E97
wdt:P1476
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
p:P304
wds:Q39961162-38A14B15-109B-4163-B373-3C571CA112D5
wdt:P304
493-497
p:P31
wds:Q39961162-213A906C-CA53-4A69-BD28-967C9B5F138D
wdt:P31
wd:Q13442814
p:P921
wds:Q39961162-0D2ECF85-0BF8-4786-98D3-67FDEF9760EA wds:Q39961162-5A766327-221E-4B0D-A03B-9F7760BC0590 wds:Q39961162-5D81FBC2-7AD6-484E-8AAF-035FDDA20EB8 wds:Q39961162-AE024D5A-8702-4EEA-9A2F-15B9D4ABB7B4
wdt:P921
wd:Q12859063 wd:Q412197 wd:Q42824440 wd:Q420436
p:P698
wds:Q39961162-FD18DE66-974A-4AC6-8B95-5EB3FDD305DE
wdtn:P698
n11:19625343
wdt:P698
19625343
p:P1433
wds:Q39961162-DE1CC4B2-4761-4A65-86E2-A9EA637641A3
wdt:P1433
wd:Q326122
p:P433
wds:Q39961162-3C9CC857-6D6E-4606-9A9F-D1B393EABD2F
p:P478
wds:Q39961162-4F7C9F36-7F4B-4A21-823D-02B81D6BC28B
wdt:P433
3
wdt:P478
21
p:P356
wds:Q39961162-26E33092-543D-4D6C-B5F6-4CB45850157B
wdtn:P356
n9:MDP328
wdt:P356
10.1093/ANNONC/MDP328
p:P8608
wds:Q39961162-25BC283E-8867-4B17-BE30-30DA40409BAE
wdt:P8608
release_on6edlqtffh7zfhqleui5gwzxi
p:P932
wds:Q39961162-AB12E7FE-9907-4F4F-95D9-6DD75C23930D
wdt:P932
5808723